# Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

> **NCT00275821** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 353 (actual)

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab 0.3 mg - 3 times monthly, then quarterly
- **DRUG:** Ranibizumab 0.5 mg - 3 times monthly, then quarterly
- **DRUG:** Ranibizumab 0.3 mg monthly

## Key facts

- **NCT ID:** NCT00275821
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 353 (ACTUAL)
- **Last updated:** 2011-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00275821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00275821, "Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT00275821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*